Health
China Sinopharm’s potential COVID-19 vaccine triggers antibodies in clinical trials: Journal – CGTN
The potential vaccine appeared to be safe and can trigger an immune response.
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
The candidate has already moved into a late-stage trial, one of a handful of candidates being tested on several thousand people to see if they are effective enough to win regulatory approval.
Sinopharm is testing the potential vaccine in the United Arab Emirates in a Phase 3 tria…
-
General22 hours agoByford rail extension opening marks final stage of Perth Metronet
-
General23 hours agoMango the muster cat draws attention to western Queensland’s ongoing recovery
-
General15 hours agoAustralia’s Diamonds defeat South Africa’s Proteas 65-42 in third netball Test
-
General15 hours agoThousands join pro-Palestinian rallies in towns and cities across Australia amid ceasefire